Last reviewed by Dr. Dharmender Malik on 14 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.
Introduction
Nuclear medicine therapy is, by design, very different from chemotherapy. The treatments described here — Lu-177 PSMA-617 for metastatic prostate cancer, Lu-177 DOTATATE (PRRT) for neuroendocrine tumours, investigational Ac-225 PSMA-617, Y-90 radioembolization for liver tumours, I-131 MIBG for neuroblastoma and selected NET, and high-dose I-131 for thyroid cancer — deliver targeted radiation through molecules that bind to disease-specific receptors or accumulate in specific organs. Compared with conventional cytotoxic chemotherapy, the side-effect profiles are generally narrower and more predictable. They are not absent. This article describes what is known about side effects across the principal nuclear medicine therapies — with primary-literature sourcing for the frequencies and management approaches presented.
General principles — how nuclear medicine side effects differ from chemotherapy
AI Overview · short answer
Nuclear medicine therapies have generally favourable side-effect profiles relative to conventional chemotherapy. Common effects across most radioligand therapies include fatigue and mild gastrointestinal symptoms. Specific therapy-related effects include xerostomia (dry mouth) with Lu-177 PSMA and more pronounced with Ac-225 PSMA; cytopenia (low blood counts) across most radioligand therapies with severity varying by isotope and patient marrow reserve; post-embolization syndrome with Y-90 TARE; and sialadenitis (salivary inflammation) and small-secondary-malignancy risk with high-dose I-131 thyroid therapy[1][2]. Most side effects are mild-to-moderate, time-limited, and respond to supportive management. Serious or persistent effects are uncommon when patient selection and dosimetry are rigorous.
Several biological and procedural features explain why nuclear medicine therapy generally has a narrower side-effect profile than systemic chemotherapy[3]:
- Targeted delivery — radioligands bind selectively to receptors expressed on tumour cells (PSMA, somatostatin receptors) or accumulate selectively in target tissues (Y-90 microspheres in hepatic arterial supply; I-131 in thyroid tissue). Most non-target tissue receives a low dose.
- Short-range radiation — beta-emitters (Lu-177, Y-90, I-131) deposit energy over millimetre-scale ranges; alpha-emitters (Ac-225) over micrometre ranges. Surrounding tissue radiation exposure is limited.
- Outpatient or short-admission delivery — most therapies are given as outpatient or short-stay procedures, not multi-week regimens.
- Predictable timing of effects — fatigue and acute effects typically peak in the first 1–2 weeks; marrow effects, when they occur, follow a predictable nadir-and-recovery timeline.
That said, the specific effects vary substantially by therapy. The remainder of this article describes each in turn.
Lu-177 PSMA-617 — side-effect profile
Side effects after Lu-177 PSMA-617 therapy were characterised in the VISION randomised trial and have been confirmed across multiple cohort studies including Indian published experience[4]:
| Side effect | Frequency & severity | Notes & management |
|---|
| Fatigue | Common; usually mild-moderate; resolves over days-weeks | Most common reported effect; supportive management |
| Xerostomia (dry mouth) | Common; usually mild-moderate | Reflects salivary gland PSMA expression; usually partial recovery; hydration, saliva substitutes, sugar-free chewing gum |
| Nausea / vomiting | Uncommon to mild; usually transient | Anti-emetic prophylaxis is routine |
| Cytopenia (anaemia, thrombocytopenia, leukopenia) | Common (any grade) but usually mild; serious cytopenia uncommon | Pre-cycle blood counts; dose modification or delay if needed; growth factor support occasionally |
| Renal effects | Uncommon when baseline kidney function is preserved | Pre-treatment eGFR and renal function monitoring |
| Bone marrow suppression (severe) | Rare | More likely in heavily pre-treated patients or those with extensive marrow disease |
| Bone pain flare | Uncommon | Usually responsive to standard analgesia; can be early sign of response |
The VISION trial documented Grade 3-or-higher adverse events in a minority of patients, most commonly anaemia, thrombocytopenia, and fatigue[4]. Indian institutional cohort data has confirmed broadly similar profiles[5]. Detailed clinical guidance on managing xerostomia, cytopenia, and other Lu-177 PSMA effects is available in our dedicated Lu-177 PSMA side effects article.
Lu-177 DOTATATE (PRRT) — side-effect profile
Lu-177 DOTATATE for somatostatin receptor-positive neuroendocrine tumours was characterised in the NETTER-1 randomised trial and across multiple subsequent cohort studies[6]:
| Side effect | Frequency & severity | Notes & management |
|---|
| Acute nausea | Common during amino acid infusion (renoprotective) | Anti-emetic prophylaxis; usually well-controlled |
| Fatigue | Common; usually mild-moderate; resolves over days-weeks | Supportive management |
| Cytopenia | Common (any grade); usually mild; severe rarer | Pre-cycle blood counts; growth factor support occasionally |
| Renal effects | Uncommon with concurrent amino acid renoprotection | Amino acid infusion during therapy is mandatory; kidney function monitoring |
| Hormonal crisis (carcinoid) | Uncommon but recognised; risk in functional tumours | Octreotide pre-medication for high-risk patients; carcinoid crisis monitoring |
| Therapy-related myeloid neoplasm (t-MDS / t-AML) | Rare (~2% cumulative risk in long-term follow-up) | Long-term marrow monitoring; risk factor in informed consent |
| Hair thinning | Uncommon | Mild and usually temporary |
NETTER-1 demonstrated significant progression-free survival benefit with an acceptable safety profile[6]. The rare risk of therapy-related myeloid neoplasm is a recognised long-term consideration in informed consent. For more on PRRT specifically, see our dedicated neuroendocrine tumour treatment article.
Ac-225 PSMA — side-effect profile (investigational / advanced indication)
Ac-225 PSMA-617 is an alpha-emitter radioligand therapy used principally in salvage-line mCRPC after Lu-177 PSMA progression. The side-effect profile differs from Lu-177 PSMA primarily in the severity of xerostomia and in marrow effects[7]:
- Xerostomia — substantially more pronounced than with Lu-177 PSMA; can be severe and persistent. The most quality-of-life-limiting effect for many patients. Salivary gland protection strategies and dose modification are areas of active research[8].
- Marrow toxicity — generally similar to or somewhat greater than Lu-177; serious cytopenia is more frequent in heavily pre-treated patients.
- Fatigue and nausea — similar to Lu-177 PSMA experience.
- Renal effects — uncommon when baseline function is preserved.
The greater xerostomia with Ac-225 reflects the higher linear-energy-transfer of alpha particles delivered to salivary gland tissue. Patients considering Ac-225 PSMA should expect a detailed pre-treatment discussion of xerostomia risk and quality-of-life impact[9]. For more detail see our dedicated Ac-225 PSMA therapy article.
Y-90 radioembolization (TARE) — side-effect profile
Y-90 TARE side effects have been characterised across SARAH, SIRveNIB, LEGACY, and multiple cohort studies in HCC, NET, and colorectal liver metastases[10]:
| Side effect | Frequency & severity | Notes & management |
|---|
| Post-embolization syndrome | Common; usually mild; resolves in 1–2 weeks | Low-grade fever, fatigue, mild abdominal discomfort, nausea; generally milder than after TACE |
| Fatigue | Common; can persist weeks | Often the most prominent residual symptom |
| Radiation-induced liver disease (REILD) | Uncommon; serious when it occurs | Risk varies with liver reserve and dose; minimised by careful dosimetry and selection |
| Cholecystitis | Uncommon | Reduced by mapping to avoid cystic artery |
| GI ulceration | Uncommon | Reduced by embolizing aberrant vessels to the gut at mapping |
| Radiation pneumonitis | Rare | Reduced by pre-procedure Tc-99m MAA lung shunt assessment |
| Biliary stricture | Uncommon | More frequent in intrahepatic cholangiocarcinoma populations |
Patient selection, careful mapping angiography, lung shunt fraction assessment, and dosimetric planning are the most important determinants of Y-90 safety[11]. For more on Y-90 specifically, see our companion Use of Yttrium-90 and its effects article and the TARE recovery and aftercare article.
I-131 MIBG — side-effect profile
I-131 MIBG is used for neuroblastoma and selected catecholamine-secreting neuroendocrine tumours including pheochromocytoma and paraganglioma. The side-effect profile reflects both the radiopharmaceutical itself and the diseases treated[12]:
- Cytopenia — common; can be substantial in heavily pre-treated neuroblastoma patients. May require growth factor support or stem-cell rescue in some protocols.
- Hypertension — particularly during therapy of catecholamine-secreting tumours; requires careful pre-treatment alpha-blockade and intra-treatment monitoring.
- Hypothyroidism — common late effect; iodine pre-blockade (potassium iodide) reduces but does not eliminate risk. Thyroid function monitoring is standard.
- Nausea and vomiting — common during and shortly after therapy.
- Therapy-related myeloid neoplasm — rare late effect; cumulative risk consideration in long-term follow-up.
I-131 MIBG is generally given inpatient under radiation-isolation protocols because of the higher external radiation exposure and the iodine content of the therapy. For more, see our neuroendocrine tumour treatment article.
I-131 high-dose thyroid therapy — side-effect profile
High-dose I-131 used after thyroidectomy for differentiated thyroid cancer has a well-characterised side-effect profile, with substantial follow-up data spanning decades[13]:
| Side effect | Frequency & severity | Notes & management |
|---|
| Sialadenitis (salivary inflammation) | Common; usually mild; can be persistent | Lemon drops, hydration, and saliva-stimulating measures; severity dose-dependent |
| Xerostomia | Common; usually mild-moderate | Often persistent; managed with hydration and saliva substitutes |
| Acute neck discomfort | Uncommon; usually mild | Particularly in patients with thyroid remnant |
| Nausea | Common in early days; usually mild | Anti-emetic prophylaxis |
| Bone marrow suppression | Uncommon at standard doses; more frequent at very high cumulative doses | Monitored particularly for retreatment patients |
| Secondary malignancy | Rare; small absolute increased risk at high cumulative doses | Documented in long-term follow-up cohorts; considered in retreatment decisions |
| Pulmonary fibrosis | Rare | Risk consideration in patients with diffuse pulmonary metastases |
| Fertility / gonadal effects | Generally minor at standard doses | Counselling around pregnancy timing post-therapy is standard |
For practical guidance for patients undergoing I-131 thyroid therapy, see our companion Iodine-131 cancer treatment article.
Red-flag symptoms — when to contact the treating centre
Across all nuclear medicine therapies, certain symptoms warrant prompt contact with the treating centre rather than waiting for routine follow-up[14]:
- Fever above 38°C / 100.4°F — particularly with chills, especially in the first 1–2 weeks after therapy when transient neutropenia may be present.
- Persistent or worsening abdominal pain — after Y-90 TARE, beyond expected post-embolization syndrome.
- New or worsening shortness of breath — particularly in the weeks after Y-90 or in I-131-treated patients with pulmonary metastases.
- Heavy or unusual bleeding — particularly nosebleeds that won't stop, gum bleeding, blood in urine or stool, suggesting low platelets.
- Severe or persistent vomiting — beyond expected acute post-therapy nausea, particularly if interfering with hydration or oral medications.
- New or worsening neurological symptoms — confusion, severe headache, weakness.
- Substantial fall in urine output — particularly after radioligand therapy where renal function is a consideration.
- Persistent fevers, mouth ulcers, or unexplained fatigue beyond expected timeline — could signal infection in the setting of unrecognised cytopenia.
How side-effect profiles factor into treatment decisions
Side-effect profiles influence treatment selection in several ways[15]:
- Patient marrow reserve — heavily pre-treated patients with thrombocytopenia or anaemia at baseline may require dose modification, alternative-line therapy, or selection of a different radionuclide.
- Renal function — pre-treatment eGFR informs candidacy for radioligand therapy and dictates renoprotective protocols (amino acid co-infusion for PRRT).
- Liver function — Child-Pugh status determines candidacy for Y-90 TARE and dose-volume planning.
- Quality-of-life priorities — for example, patients for whom severe xerostomia would be particularly burdensome (singers, professionals depending on speech) require detailed counselling regarding Ac-225 PSMA versus Lu-177 PSMA.
- Concurrent therapies — bone-targeted agents, ARPI continuation, and other concurrent treatments all factor into the cumulative side-effect picture.
The structured pre-treatment workup at an experienced centre is designed to anticipate, document, and plan around all of these — so that side-effect surprises are minimised.
The bottom line
- Nuclear medicine therapies have generally favourable side-effect profiles relative to conventional cytotoxic chemotherapy, with predictable timing and dose-dependent severity[3].
- Lu-177 PSMA-617 most commonly causes fatigue, xerostomia, mild cytopenia, and mild GI symptoms; severe effects are uncommon when patient selection is rigorous[4].
- Lu-177 DOTATATE has a similar profile with the addition of amino acid infusion-related nausea, occasional carcinoid concerns in functional tumours, and a rare long-term risk of therapy-related myeloid neoplasm[6].
- Ac-225 PSMA-617 has a similar profile to Lu-177 PSMA with substantially more pronounced xerostomia; salivary gland protection and dose modification are areas of active research[7].
- Y-90 TARE most commonly causes mild post-embolization syndrome and fatigue; serious effects (REILD, cholecystitis, GI ulceration, pneumonitis) are uncommon when mapping and selection are rigorous[10].
- I-131 MIBG and high-dose I-131 thyroid therapy have well-characterised profiles with sialadenitis, xerostomia, hypothyroidism (MIBG), and rare long-term marrow and secondary malignancy considerations[12][13].
- Red-flag symptoms (fever above 38°C, severe abdominal pain, shortness of breath, unusual bleeding, severe vomiting, neurological changes) warrant prompt contact with the treating centre, not waiting for the next scheduled review.
Important
This article is general information about side effects across nuclear medicine therapies. Individual side-effect profiles depend on the specific therapy, patient factors, comorbidities, prior treatments, and dose. Side-effect counselling specific to a planned therapy should be obtained from the treating nuclear medicine team as part of informed consent.
"Nuclear medicine side effects are not random — they are predictable, dose-dependent, and reflect the biology of the target organs. A patient who knows what to expect, when to expect it, and when to call for help is a patient who tolerates therapy better and gets the most out of it. Informed consent is not a single document signed at the start; it is an ongoing conversation that runs through every cycle of treatment."
Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI
Therapy consultation · side-effect counselling at FMRI
At FMRI Gurugram, every nuclear medicine therapy is preceded by a structured side-effect counselling discussion — covering common, uncommon, and rare effects specific to the patient's planned therapy, expected timelines, what supportive measures are in place, and what symptoms warrant prompt contact. This is part of standard informed consent and treatment planning.
Request consultation · WhatsApp +91 8800 988936
For patients & referring clinicians
Frequently asked questions
Q01
What are the most common side effects of nuclear medicine treatment?
Across most nuclear medicine therapies, the most common side effects are fatigue (common across all radioligand therapies), mild gastrointestinal symptoms (nausea, mild appetite reduction), and mild blood-count changes. Therapy-specific common effects include xerostomia (dry mouth) with Lu-177 PSMA and more pronounced with Ac-225 PSMA, post-embolization syndrome with Y-90 TARE, and sialadenitis with high-dose I-131 thyroid therapy. Most common effects are mild-to-moderate and time-limited [1][2].
Q02
Are nuclear medicine side effects worse than chemotherapy?
Generally no. Nuclear medicine therapies have narrower and more predictable side-effect profiles than conventional cytotoxic chemotherapy. The targeted nature of delivery (radioligands binding to disease-specific receptors, or accumulation in target tissues) and the short range of beta and alpha particles mean most non-target tissues receive a low dose. Comparative quality-of-life data from VISION, NETTER-1, SARAH, and other randomised trials generally favour nuclear medicine therapies over comparator regimens [3].
Q03
Will I lose my hair after Lu-177 PSMA or PRRT?
No. Lu-177 PSMA-617 and Lu-177 DOTATATE do not typically cause the substantial hair loss seen with cytotoxic chemotherapy. Mild hair thinning has been reported in a minority of patients, particularly after multiple cycles, and is usually temporary [4][6].
Q04
What is xerostomia and why does it happen with Lu-177 PSMA?
Xerostomia is dry mouth caused by reduced salivary gland function. After Lu-177 PSMA therapy, it occurs because salivary glands express low baseline levels of PSMA, so they receive some uptake of the PSMA-targeting radioligand. The effect is usually mild-moderate and partially reversible. With Ac-225 PSMA-617 (alpha-emitter), xerostomia is more pronounced and is the most quality-of-life-limiting effect for many patients. Salivary gland protection strategies are an active research area [4][8].
Q05
What is post-embolization syndrome after Y-90?
Post-embolization syndrome is a common but usually mild constellation of symptoms after Y-90 radioembolization (TARE), including low-grade fever, fatigue, mild abdominal discomfort, and mild nausea. It typically resolves within 1–2 weeks with supportive care (anti-emetics, hydration, analgesia as needed). It is generally milder than the equivalent syndrome after TACE because Y-90 microspheres cause less particle burden and ischaemic effect [10][11].
Q06
What is radiation-induced liver disease (REILD)?
Radiation-induced liver disease is an uncommon but serious complication of Y-90 TARE characterised by liver dysfunction, ascites, and jaundice typically presenting weeks to months after treatment. Risk varies with liver reserve and dose delivered to non-tumour liver; it is more likely in patients with reduced baseline liver function or after whole-liver treatment. Careful dosimetry and patient selection are the most important determinants of REILD risk [11].
Q07
Can nuclear medicine therapy cause secondary cancer?
Some nuclear medicine therapies carry a small absolute risk of therapy-related myeloid neoplasm (t-MDS / t-AML) at long follow-up — most documented after Lu-177 DOTATATE (~2% cumulative in long-term follow-up). High-dose I-131 thyroid therapy carries a small increased risk of secondary malignancy at very high cumulative doses. These risks are real but small in absolute terms and are weighed against the disease being treated as part of informed consent [6][13].
Q08
How long do nuclear medicine side effects last?
Most acute side effects (fatigue, nausea, post-embolization syndrome) resolve within 1–2 weeks. Cytopenia, when it occurs, typically follows a nadir-and-recovery timeline over 2–4 weeks. Xerostomia may persist for months or be partially permanent. Hypothyroidism after I-131 MIBG is typically permanent and requires lifelong thyroxine replacement. Specific timelines are discussed at the side-effect counselling for each therapy [14].
Q09
When should I call the centre after therapy?
Contact the treating centre promptly for: fever above 38°C / 100.4°F (particularly with chills), severe or worsening abdominal pain after Y-90 TARE, new shortness of breath, heavy or unusual bleeding (nosebleeds, gum bleeding, blood in urine or stool), severe persistent vomiting, new neurological symptoms (confusion, severe headache, weakness), substantial fall in urine output, or persistent symptoms beyond the expected timeline. These are the red-flag symptoms — do not wait for the next scheduled review [14].
Q10
Are family members at risk from radiation after my therapy?
For most nuclear medicine therapies, external radiation exposure to family members is low and manageable with brief common-sense distancing measures for the first few days. High-dose I-131 thyroid therapy and I-131 MIBG involve higher external exposure and typically require inpatient isolation for the first 1–3 days, followed by specific written discharge instructions covering distance, sleeping arrangements, bathroom use, and contact with children and pregnant women. Specific guidance is provided at discharge for each therapy [3][13].
Q11
Will side effects affect my eligibility for further cycles?
Side-effect severity is one of several factors that determine whether further cycles are appropriate. Specifically, severe cytopenia or worsening kidney function may require dose modification, treatment delay, or switching to alternative therapy. Mild and expected side effects rarely affect continued therapy. Decisions about further cycles are made by the multidisciplinary team weighing response, tolerability, and the patient's overall clinical picture [15].
Q12
How do I get side-effect counselling at FMRI?
At FMRI Gurugram, every nuclear medicine therapy is preceded by a structured side-effect counselling discussion covering common, uncommon, and rare effects specific to the planned therapy, expected timelines, supportive measures, and red-flag symptoms warranting prompt contact. This is part of standard informed consent and treatment planning. WhatsApp +91 8800 988936 to request a consultation.
Citations & references
All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the regulatory archive — open in a new tab to verify.
[1] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of
177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1).
N Engl J Med. 2017;376(2):125-135.
View source ↗[2] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION).
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[3] European Association of Nuclear Medicine. EANM procedure guidelines for radionuclide therapy.
View source ↗[4] Hennrich U, Eder M.
177Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Pharmaceuticals (Basel). 2022;15(10):1292.
View source ↗[5] Yadav MP, Ballal S, Tripathi M, et al.
177Lu-DKFZ-PSMA-617 therapy in mCRPC: Indian experience.
Eur J Nucl Med Mol Imaging. 2017;44(1):81-91.
View source ↗[6] Strosberg JR, Caplin ME, Kunz PL, et al.
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut NETs (NETTER-1): final overall survival.
Lancet Oncol. 2021;22(12):1752-1763.
View source ↗[7] Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-therapy of mCRPC with
225Ac-PSMA-617: dosimetry and toxicity.
J Nucl Med. 2017;58(10):1624-1631.
View source ↗[8] Sathekge M, Bruchertseifer F, Knoesen O, et al.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer.
Eur J Nucl Med Mol Imaging. 2019;46(1):129-138.
View source ↗[9] Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of outcome in mCRPC receiving
225Ac-PSMA-617.
J Nucl Med. 2020;61(1):62-69.
View source ↗[10] Vilgrain V, Pereira H, Assenat E, et al. SARAH: SIRT vs sorafenib in advanced HCC.
Lancet Oncol. 2017;18(12):1624-1636.
View source ↗[11] Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors.
Cancer. 2008;112(7):1538-1546.
View source ↗[12] Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
J Clin Oncol. 2007;25(9):1054-1060.
View source ↗[13] Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.
J Clin Endocrinol Metab. 1986;63(4):960-967.
View source ↗[14] Iravani A, Violet J, Azad A, et al. Lutetium-177 PSMA therapy: practical aspects, dosimetry, and outcomes.
Theranostics. 2020;10(20):8854-8866.
View source ↗[15] Hofman MS, Emmett L, Sandhu S, et al. [
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with mCRPC (TheraP).
Lancet. 2021;397(10276):797-804.
View source ↗[16] Hofman MS, Violet J, Hicks RJ, et al. [
177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial).
Lancet Oncol. 2018;19(6):825-833.
View source ↗[17] Basu S, Parghane RV, Banerjee S, et al. Long-term outcome of
177Lu-PSMA-617 therapy in mCRPC: Indian experience.
Clin Nucl Med. 2021;46(10):820-826.
View source ↗[18] Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: PRRT.
Neuroendocrinology. 2017;105(3):295-309.
View source ↗[19] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with NETs: the value and limitations of clinical factors.
Eur J Nucl Med Mol Imaging. 2015;42(1):5-19.
View source ↗[20] Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of hepatocellular carcinoma.
Clin Gastroenterol Hepatol. 2013;11(6):604-611.
View source ↗[21] Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization.
Front Oncol. 2014;4:198.
View source ↗[22] Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: Y90 SIRT vs sorafenib in locally advanced HCC.
J Clin Oncol. 2018;36(19):1913-1921.
View source ↗[23] Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infusions of high dose
131I-MIBG for refractory neuroblastoma.
Pediatr Blood Cancer. 2005;44(3):232-239.
View source ↗[24] Sisson JC, Yanik GA. Theranostics: Evolution of the radiopharmaceutical meta-iodobenzylguanidine.
Semin Nucl Med. 2012;42(3):171-184.
View source ↗[25] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.
Thyroid. 2016;26(1):1-133.
View source ↗[26] Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase I/II study of fractionated dose
177Lu-J591.
Cancer. 2019;125(15):2561-2569.
View source ↗[27] Mittal BR, Kumar A, Sood A, et al. Practice of Nuclear Medicine Therapy in India: Audit of a Tertiary Care Centre.
Indian J Nucl Med. 2020;35(2):126-131.
View source ↗[28] Atomic Energy Regulatory Board (Government of India). Safety Code for Nuclear Medicine Facilities. AERB/RF-MED/SC-2 (Rev. 2).
View source ↗[29] Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for PRRT.
Pharmaceuticals (Basel). 2019;12(3):114.
View source ↗[30] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges.
Nat Rev Drug Discov. 2020;19(9):589-608.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.